Necrosulfonamide

Cat. No.: HY-100573 Purity: 98.84%: FAQs
Data Sheet SDS COA Handling Instructions

Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis.

For research use only. We do not sell to patients.

Necrosulfonamide Chemical Structure

CAS No. : 1360614-48-7

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solution
10 mM * 1 mL in DMSO	USD 87	In-stock	Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL ready for reconstitution	USD 87	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 79	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 106	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 198	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 290	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 528	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 58 publication(s) in Google Scholar

Other Forms of Necrosulfonamide:

(E/Z)-Necrosulfonamide Get quote

57 Publications Citing Use of MCE Necrosulfonamide

: Necrosulfonamide purchased from MCE. Usage Cited in: Transl Stroke Res. 2021 Dec;12(6):991-1017. [Abstract]; Delayed administration of Necrosulfonamide (NSA) reduces the protein level of RIP3K or MLKL and GFAP after OGD/Re injury. Astrocytes are exposed to OGD for 6 h followed by reoxygenation for 24 h. NSA (1 μM) is added to the cells upon reoxygenation.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Necrosulfonamide specifically blocks necrosis downstream of RIP3 activation. Necrosulfonamide inhibits MLKL-mediated necrosis by blocking Its N-terminal CC domain function^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

461.47

Appearance

Solid

Formula

C₁₈H₁₅N₅O₆S₂

CAS No.

1360614-48-7

SMILES

O=C(NC1=CC=C(S(=O)(NC2=NC=CN=C2OC)=O)C=C1)/C=C/C3=CC=C([N+]([O-])=O)S3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 28 mg/mL (60.68 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1670 mL	10.8349 mL	21.6699 mL
5 mM	0.4334 mL	2.1670 mL	4.3340 mL
10 mM	0.2167 mL	1.0835 mL	2.1670 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 50% PEG300 50% saline
Solubility: 10 mg/mL (21.67 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 20% SBE-β-CD in saline
Solubility: 6.67 mg/mL (14.45 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic
4.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic
5.

Add each solvent one by one: 10% DMSO 90% corn oil
Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: 98.84%

Select Batch:

Data Sheet (272 KB) SDS (393 KB)

COA (248 KB) HNMR (284 KB) LCMS (269 KB)

Handling Instructions (2659 KB)

References

[1]. Sun L, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227. [Content Brief]